A methylated MGMT promoter showed a survival benefit in both neural subgroups, but a striking difference in low-neural glioblastoma with a median overall survival difference of 12.0 months depending on the MGMT promoter methylation status (P < 0.0001; Fig. 6c). The gene discussed is MGMT; the disease is glioblastoma.